| Heidi Ogletree, | |
|
3011 E Barnett Rd, Medford, OR 97504 | |
| (541) 789-4673 | |
| (541) 789-2121 |
| Full Name | Heidi Ogletree |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 6 Years |
| Location | 3011 E Barnett Rd, Medford, Oregon |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1952874448 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | 201810782NP-PP (Oregon) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Asante Rogue Regional Medical Center | Medford, OR | Hospital |
| Asante Three Rivers Medical Center | Grants pass, OR | Hospital |
| Providence Medford Medical Center | Medford, OR | Hospital |
| Asante Ashland Community Hospital | Ashland, OR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Asante | 0547177321 | 88 |
| Asante Three Rivers Medical Center Llc | 9931197993 | 80 |
News Archive
Cintas Corporation, a leader in first-aid and safety products, today announced the availability of GlucoBurst, a blood sugar control product for its first-aid cabinets. According to the Centers for Disease Control and Prevention (CDC), diabetes results in 15 million missed work days and 120 million work days with reduced performance each year.
TxCell SA, a biotechnology company developing innovative, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that it is operating a strategic review that should result in the outsourcing of all existing and future clinical and commercial manufacturing operations to contract manufacturing organizations (CMOs).
Cancer patients at Mercy & Unity Hospitals have access to the latest in diagnostic imaging to assess the presence and extent of most types of cancer.
AI Therapeutics announced the start of Phase II clinical trial for the treatment of newly diagnosed COVID-19 patients in collaboration with Yale University.
An international team of researchers has published a benchmark study showing that gene expression in several animal models of Huntington's Disease (HD) closely resembles that of human HD patients.
› Verified 9 days ago
| Entity Name | Asante |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770587107 PECOS PAC ID: 0547177321 Enrollment ID: O20031219000238 |
News Archive
Cintas Corporation, a leader in first-aid and safety products, today announced the availability of GlucoBurst, a blood sugar control product for its first-aid cabinets. According to the Centers for Disease Control and Prevention (CDC), diabetes results in 15 million missed work days and 120 million work days with reduced performance each year.
TxCell SA, a biotechnology company developing innovative, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that it is operating a strategic review that should result in the outsourcing of all existing and future clinical and commercial manufacturing operations to contract manufacturing organizations (CMOs).
Cancer patients at Mercy & Unity Hospitals have access to the latest in diagnostic imaging to assess the presence and extent of most types of cancer.
AI Therapeutics announced the start of Phase II clinical trial for the treatment of newly diagnosed COVID-19 patients in collaboration with Yale University.
An international team of researchers has published a benchmark study showing that gene expression in several animal models of Huntington's Disease (HD) closely resembles that of human HD patients.
› Verified 9 days ago
| Entity Name | Hematology Oncology Associates, P.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043263619 PECOS PAC ID: 1951393156 Enrollment ID: O20040330001310 |
News Archive
Cintas Corporation, a leader in first-aid and safety products, today announced the availability of GlucoBurst, a blood sugar control product for its first-aid cabinets. According to the Centers for Disease Control and Prevention (CDC), diabetes results in 15 million missed work days and 120 million work days with reduced performance each year.
TxCell SA, a biotechnology company developing innovative, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that it is operating a strategic review that should result in the outsourcing of all existing and future clinical and commercial manufacturing operations to contract manufacturing organizations (CMOs).
Cancer patients at Mercy & Unity Hospitals have access to the latest in diagnostic imaging to assess the presence and extent of most types of cancer.
AI Therapeutics announced the start of Phase II clinical trial for the treatment of newly diagnosed COVID-19 patients in collaboration with Yale University.
An international team of researchers has published a benchmark study showing that gene expression in several animal models of Huntington's Disease (HD) closely resembles that of human HD patients.
› Verified 9 days ago
| Entity Name | Asante Three Rivers Medical Center Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801891809 PECOS PAC ID: 9931197993 Enrollment ID: O20040506000367 |
News Archive
Cintas Corporation, a leader in first-aid and safety products, today announced the availability of GlucoBurst, a blood sugar control product for its first-aid cabinets. According to the Centers for Disease Control and Prevention (CDC), diabetes results in 15 million missed work days and 120 million work days with reduced performance each year.
TxCell SA, a biotechnology company developing innovative, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that it is operating a strategic review that should result in the outsourcing of all existing and future clinical and commercial manufacturing operations to contract manufacturing organizations (CMOs).
Cancer patients at Mercy & Unity Hospitals have access to the latest in diagnostic imaging to assess the presence and extent of most types of cancer.
AI Therapeutics announced the start of Phase II clinical trial for the treatment of newly diagnosed COVID-19 patients in collaboration with Yale University.
An international team of researchers has published a benchmark study showing that gene expression in several animal models of Huntington's Disease (HD) closely resembles that of human HD patients.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Heidi Ogletree, Po Box 4749, Medford, OR 97501-0227 Ph: (541) 789-4111 | Heidi Ogletree, 3011 E Barnett Rd, Medford, OR 97504 Ph: (541) 789-4673 |
News Archive
Cintas Corporation, a leader in first-aid and safety products, today announced the availability of GlucoBurst, a blood sugar control product for its first-aid cabinets. According to the Centers for Disease Control and Prevention (CDC), diabetes results in 15 million missed work days and 120 million work days with reduced performance each year.
TxCell SA, a biotechnology company developing innovative, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that it is operating a strategic review that should result in the outsourcing of all existing and future clinical and commercial manufacturing operations to contract manufacturing organizations (CMOs).
Cancer patients at Mercy & Unity Hospitals have access to the latest in diagnostic imaging to assess the presence and extent of most types of cancer.
AI Therapeutics announced the start of Phase II clinical trial for the treatment of newly diagnosed COVID-19 patients in collaboration with Yale University.
An international team of researchers has published a benchmark study showing that gene expression in several animal models of Huntington's Disease (HD) closely resembles that of human HD patients.
› Verified 9 days ago
Helen Koenigsman, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1333 E Barnett Rd, Medford, OR 97504 Phone: 541-779-4711 | |
Dr. Todd S Kotler, M.D. Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 520 Medical Center Drive, Ste 200, Medford, OR 97504 Phone: 541-282-6606 Fax: 541-282-6601 | |
Dr. Mark G Moran, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 520 Medical Center Drive, Ste 200, Medford, OR 97504 Phone: 541-282-6606 Fax: 541-282-6601 | |
Dr. June Symens, M.D. Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 555 Black Oak Dr Ste 400, Medford, OR 97504 Phone: 541-821-6090 | |
Donald L Bowser, NP Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 520 Medical Center Dr, Suite 100, Medford, OR 97504 Phone: 541-789-5704 Fax: 541-789-5989 | |
Samridhi Amba, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 827 Spring St, Medford, OR 97504 Phone: 541-732-7600 | |
Margaret Sara Fairhurst, D.O. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1698 E Mcandrews Rd Ste 400, Medford, OR 97504 Phone: 541-732-7960 |